Market Research Report
Insulin Like Growth Factor I - Pipeline Review, H1 2019
|Published by||Global Markets Direct||Product code||408077|
|Published||Content info||53 Pages
Delivery time: 1-2 business days
|Insulin Like Growth Factor I - Pipeline Review, H1 2019|
|Published: June 10, 2019||Content info: 53 Pages||
According to the recently published report 'Insulin Like Growth Factor I - Pipeline Review, H1 2019'; Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) pipeline Target constitutes close to 9 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Insulin-like growth factor 1 (IGF-1) also called somatomedin C is a protein encoded by the IGF1 gene. It stimulates glucose transport in bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin. It plays a role in synapse maturation. It acts as a ligand for IGF1R. It binds to the alpha subunit of IGF1R, leading to the activation of the intrinsic tyrosine kinase activity which autophosphorylates tyrosine residues in the beta subunit thus initiates a cascade of down-stream signaling events leading to activation of the PI3K-AKT/PKB and the Ras-MAPK pathways. It binds to integrins ITGAV: ITGB3 and ITGA6:ITGB4. It also binds to integrins and subsequent ternary complex formation with integrins and IGFR1 are essential for IGF1 signaling.
The report 'Insulin Like Growth Factor I - Pipeline Review, H1 2019' outlays comprehensive information on the Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 2 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.
Report covers products from therapy areas Oncology, Cardiovascular and Central Nervous System which include indications Acute Ischemic Stroke, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Breast Cancer, Cerebral Infarction (Brain Infarction), Huntington Disease, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Sclerosis, Neuroblastoma, Neuroendocrine Tumors, Neuropathic Pain (Neuralgia), Non-Small Cell Lung Cancer, Parkinson's Disease, Peripheral Nerve Injury, Prostate Cancer and Solid Tumor.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.